Mind the Gap in Kidney Care: Translating What We Know Into What We Do.


Journal

Iranian journal of kidney diseases
ISSN: 1735-8604
Titre abrégé: Iran J Kidney Dis
Pays: Iran
ID NLM: 101316967

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 19 04 2024
medline: 25 4 2024
pubmed: 25 4 2024
entrez: 25 4 2024
Statut: ppublish

Résumé

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions worldwide are diagnosed, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because in the early stages it is often silent. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from patient to clinician to health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay. DOI: 10.52547/ijkd.8216.

Identifiants

pubmed: 38660692
pii: 8171/1463
doi: 10.5254/sqbbj216
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

68-86

Auteurs

Valerie A Luyckx (VA)

Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.

Katherine R Tuttle (KR)

Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, USA.

Dina Abdellatif (D)

Department of Nephrology, Cairo University Hospital, Cairo, Egypt.

Ricardo Correa-Rotter (R)

Department of Nephrology and Mineral Metabolism, National Medical Science and Nutrition Institute Salvador Zubiran, Mexico City, Mexico.

Winston W S Fung (WWS)

Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China.

Agnès Haris (A)

Nephrology Department, Péterfy Hospital, Budapest, Hungary.

Li-Li Hsiao (LL)

Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Makram Khalife (M)

ISN Patient Liaison Advisory Group.

Latha A Kumaraswami (LA)

Tamilnad Kidney Research (TANKER) Foundation, Chennai, India.

Fiona Loud (F)

ISN Patient Liaison Advisory Group.

Vasundhara Raghavan (V)

ISN Patient Liaison Advisory Group.

Stefanos Roumeliotis (S)

2nd Department of Nephrology, AHEPA University Hospital Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Marianella Sierra (M)

ISN Patient Liaison Advisory Group.

Ifeoma Ulasi (I)

Department of Medicine, College of Medicine, University of Nigeria, Ituku-Ozalla, Enugu, Nigeria.

Bill Wang (B)

ISN Patient Liaison Advisory Group.

Siu-Fai Lui (SF)

Division of Health System, Policy and Management, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong.

Vassilios Liakopoulos (V)

2nd Department of Nephrology, AHEPA University Hospital Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Alessandro Balducci (A)

Italian Kidney Foundation, Rome, Italy.

Or The World Kidney Day Joint Steering Committee (OTWKD)

The World Kidney Day Joint Steering Committee is listed in the Appendix.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH